No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AEMD Aethlon Medical
- 0.5729
- -0.0518-8.29%
Trading Jun 26 15:58 ET
5.29MMarket Cap-114P/E (TTM)
0.6209High0.5500Low1.88MVolume0.6200Open0.6247Pre Close1.09MTurnover20.83%Turnover RatioLossP/E (Static)9.23MShares5.000052wk High0.38P/B5.17MFloat Cap0.370452wk Low--Dividend TTM9.02MShs Float67499.9865Historical High--Div YieldTTM11.35%Amplitude0.3704Historical Low0.5800Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Aethlon Medical Is Maintained at Buy by HC Wainwright & Co.
Aethlon Medical Is Maintained at Buy by HC Wainwright & Co.
Aethlon Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/24/2024 1098.84% HC Wainwright & Co. $10 → $7 Maintains Buy 03/04/2024 1612.62% HC Wainwright & Co. $23
Express News | Aethlon Medical Inc : H.c. Wainwright Cuts Target Price to $7 From $10
What's Next in Treatments for Cancer Patients With Solid Tumors?
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of sol
Express News | Aethlon Medical Shares Are Trading Higher After the Company Received Ethics Committee Approval for Its Hemopurifier Clinical Trial in Cancer Patients With Solid Tumors Unresponsive to Anti-PD-1 Therapy
Express News | Aethlon Medical Receives Full Ethics Approval for Hemopurifier Clinical Trial in Cancer Patients With Solid Tumors Unresponsive to Anti-PD-1 Therapy
Comments
$Aethlon Medical(AEMD.US$ buy the dip! and let it rip!
$Aethlon Medical(AEMD.US$ sec 201 will be active tommorow if i'm not wrong!
3
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial.
Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering medical therapeutic company dedicated to developing advanced treatments for cancer and life-threatening infectious diseases, has reached a milestone in its quest to improve cancer therapy outcomes. On June 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Healt...
Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering medical therapeutic company dedicated to developing advanced treatments for cancer and life-threatening infectious diseases, has reached a milestone in its quest to improve cancer therapy outcomes. On June 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Healt...
6
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
I Am 102927471 :